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Abstract 
The effect of a nitric oxide (NO) donor GEA 3162 on the endothelial cell (EC)-mediated oxidation of low density lipoprotein (LDL) was studied. 
In comparison to LDL incubated with EC without GEA 3 162, the presence of GEA 3 162 inhibited LDL oxidation by EC, as indicated by the following 
findings. (a) The degradation rate of LDL in macrophages was reduced to control levels. (b) The electrophoretic mobility of LDL decreased in a 
dose-dependent manner. (c) The concentrations of thiobarbituric acid-reactive substances and hydroperoxide-derived hydroxy fatty acids were lower. 
(d) The breakdown of apolipoprotein B was reduced. The results indicate that GEA 3162 prevents EC-mediated oxidation of LDL. 
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1. Introduction 
Oxidative modification of low density lipoprotein NO is a short-lived, rapidly diffusable biological mes- 
(LDL) may play an important role in the pathogenesis senger molecule, which can cause many metabolic 
of atherosclerosis [l]. Oxidized LDL has been isolated changes in target cells [ 131. In EC, NO has been reported 
from atherosclerotic lesions [2], and antioxidant therapy to lead to autocrine stimulation of cGMP [14] and to 
reduces atherogenesis in animal models [3,4]. Previous function as a negative feedback modulator of its own 
studies of cell-mediated LDL oxidation have demon- synthesis [ 151. NO is also a free radical and when reacting 
strated that all cell types present in atherosclerotic le- with O;, it can produce a potent oxidant peroxynitrite 
sions can oxidize LDL [5-81. The mechanisms whereby [16]. Protonated peroxynitrite has been proposed to 
different cell types oxidize LDL particles are still un- decay to hydroxyl radical, Indeed, simultaneous genera- 
known, although several mechanisms, such as lipoxyge- tion of 0; and NO by SIN-l has been demonstrated to 
nases [9, lo], superoxide anions (0;) [7], and peroxynitrite initiate lipid peroxidation in human LDL [l 1,17,18] and 
(ONOO-) [l l] have been suggested to play roles in this to convert LDL to a form recognized by macrophage 
process. scavenger eceptor [ 171. 
Oxidation causes significant changes in several prop- 
erties of LDL [ 1,121. Among these changes are increased 
electrophoretic mobility, increased contents of fatty acid 
peroxides and thiobarbituric acid-reactive substances 
(TBARS), breakdown of apolipoprotein B and increased 
degradation rate by macrophages. These properties of 
The purpose of the present study was to investigate the 
effects of a potent NO donor GEA 3162 on the EC- 
mediated oxidation of LDL. It was found that the NO 
donor inhibited rabbit aortic EC-mediated oxidation of 
LDL. 
oxidized LDL were used in the present study as indica- 
tors of LDL oxidation. 
2. Materials and methods 
*Corresponding author. Fax: (358) (31) 2156661. 
Abbreviations: EC, endothelial cells; DMEM, Dulbecco’s modified 
Eagle’s medium; LDL, low density lipoprotein; LPDS, lipoprotein- 
deficient serum; MDA, malondialdehyde; NO, nitric oxide; O;, super- 
oxide anion; SDS-PAGE, SDS-polyacrylamide gel electrophoresis; 
TBARS, thiobarbituric acid-reactive substances; SIN-1,3-morpholino- 
sydnonimine-hydrochloride. 
2.1. Materials 
Carrier-free sodium ‘*‘I was purchased from Amersham (Bucking- 
hamshire, UK). Optimem-1, RPMI-1640, Dulbecco’s modified Eagle’s 
medium (DMEM), Newborn calf serum, Penicillin-Streptomycin and 
Gentamycin were from Gibco laboratories (Paisley, Scotland). Endo- 
thelial cell-derived growth supplement, 4chloro-1-naphthol, butylated 
hydroxytoluene, glyceryltriheptadecanoate nd reference methyl esters 
of hydroxy fatty acids were from Sigma Chemical Co. (St. Louis, MO, 
0014-5793/94/$7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
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USA). Agarose gels were purchased from Corning Diagnostics (Palo 
Alto, CA, USA). Cell culture dishes were from Nunclon (Roskilde, 
Denmark). NO donor GEA 3162 was kindly provided by GEA Ltd. 
(Copenhagen, Denmark). GEA 3162 is a mesoionic 3-aryl-substituted 
oxatriazole-5-imine derivative (Fig. 1) which produces NO upon de- 
composition [19,20]. NO donor 3-morpholino-sydnonimine-hydrochlo- 
ride (SIN-l) was obtained from GEA Ltd. X-ray films were purchased 
from Eastman Kodak Co. (Rochester, NY, USA). DB-I columns were 
from J & W Scientific, Inc. (Ranch0 Cordova, CA, USA). Nitrocellu- 
lose membranes and molecular weight markers were from Bio-Rad 
Laboratories (Richmond, CA, USA). Peroxidase-conjugated goat anti- 
guinea pig antibodies were from Dakopatts (Copenhagen, Denmark). 
2.2. Cell cultures 
Rabbit aortic EC [21] were grown in RPMI-1640 medium supple- 
mented with heat-inactivated 10% newborn calf serum, 1.6 mM L- 
glutamine, 10 mM HEPES, 300 U/ml penicillin, lOO,@ml streptomycin 
and 10 &ml endothelial cell-derived growth supplement. Cells were 
grown in a humidified atmosphere containing 5% CO* and fed three 
times a week. Peritoneal macrophages were harvested from male 
NMRI mice and washed two times with phosphate-buffered saline 
(PBS). The cells were added to tissue culture plates in serum-free 
DMEM and cultured for 2 h at 37°C. The non-adherent cells were 
washed off and monolayers were then placed in DMEM containing 
10% newborn calf serum and cultured for 24 h. In all macrophage 
experiments the medium was replaced with Optimem-1 supplemented 
with 5% human lipoprotein-deficient serum (LPDS), glutamine and 
antibiotics. 
2.3, LDL mod$cation and degradation analyses 
Human plasma LDL was isolated from healthy donors by sequential 
ultracentrifugation at a density of 1.019-1.063 g/ml [22]. Lipoproteins 
were labeled with carrier-free sodium ?-iodide as described [23]. LDL 
protein concentrations were determined according to Lowry et al. [24]. 
TBARS were analyzed as described [9] and expressed as nmol malondi- 
aldehyde (MDA)/mg LDL protein. 
EC-modified LDL was made as follows: confluent monolayers of 
rabbit aortic EC were washed with Hank’s solution, fed with fresh 
Optimem-1 without serum and exposed to 5560 fig/ml of “‘1-LDL 
(100-200 cpmlng protein) with or without the NO donor GEA 3162. 
Optimem-1 was used in all experiments, because it contains no copper 
and maintains EC functions better than most other media during 
serum-free incubations. 
Cells were incubated at 37°C for indicated times. The NO donor 
GEA 3162 was introduced into the culture medium every 8 h. At the 
end of the incubation, culture medium was collected and sterilized by 
filtration (0.45 pm). To estimate the degree of LDL modification, an 
aliquot of the EC medium was used for 1% agarose lectrophoresis (pH 
8.6). LDL was visualized on agarose gels using either Fat Red 7B 
staining or autoradiography. LPDS was added to the EC conditioned 
medium at a final concentration of 5% (which prevents further oxida- 
tion) and the medium was incubated with macrophages for another 24 
h. At the end of the incubation, culture medium was collected and LDL 
degradation was determined as trichloroacetic acid-soluble non-iodide 
radioactivity [25]. Macrophages were dissolved in 200 mM NaOH and 
assayed for protein [24]. Each cell culture experiment was performed 
at least three times using duplicate samples. No microscopic signs of 
toxicity were detected in EC or macrophage cultures during incubations 
with the NO donor GEA 3162. 
2.4. SDS-PAGE and immunoblotting 
Rabbit aortic EC were cultured with unlabelled LDL (60 fig/ml) for 
48 h and the incubation medium was collected and adjusted to the 
density of 1.2 g/ml with solid KBr. Samples were centrifuged in the 
presence of 0.01% one mM EDTA at 40,000 x g for 48 h at +lO”C 
(Beckman L-60, Palo Alto, Ca, USA). Lipoproteins were collected from 
the top of the tubes and dialyzed against lipoprotein-dialyzing buffer 
(0.9% NaCl/O.Ol% EDTA) for 48 h. SDS-PAGE was performed using 
10% gels in 0.025 M Tris/O.l9 M glycine buffer (pH 8.3) containing 
0.1% SDS (100 V, 30 mA for 75 min) [2]. Before electrophoresis, the 
samples were heated for 3 min in a boiling water bath. The sample 
buff& contained 0.063 M Tris-HCl, 2% SDS, 10% glycerol, 10 PM 
butylated hydroxytoluene, and 0.001% bromophenol blue (pH 6.8). 
Twenty pg of proteins were loaded per lane. 
Proteins were transferred to a nitrocellulose membrane in the same 
electrophoresis unit at +4”C for 80 min (25 V, 100 mA). Nonspecific 
binding sites on the membranes were blocked by incubation with 5% 
nonfat dried milk proteins [2]. The membranes were incubated for 12 
h with a polyclonal guinea pig anti-LDL antiserum YE [26], followed 
by incubation with peroxidase-conjugated anti-guinea pig antibodies. 
4-chloro-1-naphthol was used as a color substrate to visualize apolipo- 
protein B bands. 
2.5. Analysis of hydroxy fatty acids 
To a SOO-~1 aliquot of the cell culture supematant, 25 pg butylated 
hydroxytoluene was added as an antioxidant and 25 pg triheptade- 
canoin as an internal standard. Lipids were extracted with chloroform/ 
methanol (1:l) and purified according to Folch et al. 1271, followed by 
reduction of the double bonds by hydrogen gas in the presence of 
platinum oxide for 15 min. After saponification in KOH-ethanol, the 
fatty acids were esterified with dry methanol containing 2% H,SO,, 
acetylated overnight with acetic anhydride-pyridine (5: l), and fraction- 
ated in a Hewlett Packard 5890 gas chromatograph fitted with a 30-m 
0.5-mm i.d. fused silica column of DB-1, on-column inlet, flame ioniza- 
tion detector, and HP3365 ChemStation software. The temperature was 
programmed from 50 to 270°C. The peaks of hydroxyoctadecanoate 
and hydroxyeicosanoate were identified with the aid of reference methyl 
esters of hydroxy fatty acids. Nitrite generation was measured as de- 
scribed [28]. 
3. Results 
We first compared nitrite generation from GEA 3162 
and SIN-l. The initial rates of nitrite generation from 50 
PM GEA 3162 and SIN-l in DPBS at 37°C were 
1.24 + 0.04 and 0.49 + 0.03 nmol/ml/min (mean + S.E., 
n = 6), respectively. The rate of nitrite generation from 
GEA 3162 at 37°C was linear for about 5 min, while the 
linear rate of nitrite generation from SIN- 1 continued for 
at least 20 min (data not shown). 
The NO donor GEA 3 162 (3.3 PM) effectively blocked 
the oxidation-dependent increase in LDL electrophoretic 
mobility after incubation with rabbit aortic EC (Fig. 2). 
The effect of GEA 3162 was different from that of an- 
other NO-donor, SIN-l, which under the same condi- 
tions increased LDL electrophoretic mobility (Fig. 2). 
GEA 3 162 also decreased the breakdown of apolipopro- 
tein B caused by EC-mediated oxidation of LDL (Fig. 3). 
The amount of the linoleate-derived hydroxy fatty 
acids was clearly increased in the EC-oxidized LDL, but 
no increase was seen in the samples incubated with the 
NO donor GEA 3162 (Table 1). GEA 3162 also pre- 
vented an increase in LDL TBARS values after incuba- 
tion with EC (Table 1). 
The degradation rate of EC-modified LDL in mouse 
peritoneal macrophages was increased 34-fold as com- 
Cl 
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Fig. 1. The chemical structure of the NO donor GEA 3162. 
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Fig. 2. Effect of the NO donor GEA 3162 on the electrophoretic mobil- 
ity of LDL after endothelial cell-mediated oxidation. (A) Confluent 
rabbit aortic endothelial cells were incubated for 24 h with 5 @ml 
“‘1-LDL in serum-free Optimem-1 in the presence or absence of the NO 
donor GEA 3162 (3.3 PM) (B) Dose-response of the protective effect 
of the NO donor GEA 3162. (C) Effect of another NO donor SIN-l 
on the endothelial cell-mediated oxidation of LDL. Samples were ana- 
lyzed in 1% agarose electrophoresis, followed by autoradiography. C, 
control LDL; EC, endothelial cell-treated LDL; GEA 3162 and SIN-l, 
effects of various concentrations of GEA 3162 and SIN-l on the endo- 
thelial cell-mediated oxidation of LDL. An arrow indicates the point 
of application. 
pared to controls (Fig. 4A). When the NO donor GEA 
3162 was present during the incubation with EC, the 
subsequent degradation rate of LDL in macrophages 
was decreased to control values. The same effect was 
seen in cell-associated radioactivity (Fig. 4B). 
Since some of the NO donor could remain intact in the 
EC-conditioned medium after the incubations, we tested 
the direct effect of GEA 3162 on the degradation of 
acetylated LDL by macrophages. It appeared that at a 
3.3 PM concentration GEA 3162 decreased the degra- 
dation rate of acetylated LDL only by 15%. Also, in a 
cell-free system the NO donor GEA 3 162 (3.3 yM) alone 
was unable to oxidize LDL to a form recognized by 
macrophages nor did it inhibit copper-induced oxidation 
of LDL (data not shown). 
4. Discussion 
Oxidized LDL possesses everal atherogenic proper- 
ties: it can lead to the formation of foam cells, it is 
Table 1 
Effect of the NO donor GEA 3 162 on the content of hydroxy fatty acids 
in LDL after endothelial cell-mediated oxidation 
Control 
LDL 
Endothelial 
treated LDL 
GEA 3162 
- + 
Hydroxy fatty acids 
Wmg LDL) 
OH-octadecanoate 
(OH-18) 
OH-eicosanoate 
(OH-20) 
TBARS (nmol MDA/mg LDL) 
14.5 71.8 5.7 
8.4 8.0 4.8 
16 64 10 
LDL (80 &ml) was incubated with endothelial cells in serum-free 
Optimem-1 medium for 48 h in the presence (3.3 PM) or absence of the 
NO donor GEA 3162. The lipids were extracted from the incubation 
medium with chloroform/methanol, hydrogenated and saponified. The 
fatty acids were then esterified and analyzed with gas chromatography. 
Control LDL was kept under similar conditions at 4°C for 48 h. The 
table gives results of a representative experiment. Similar results were 
obtained after a 24 h incubation time (data not shown). 
chemotactic for blood monocytes and cytotoxic to EC 
[l]. Various forms of oxidized LDL can also induce 
changes in arterial wall gene expression [29] and inhibit 
EC-derived relaxing factor-mediated vasodilation [30]. 
All cell types found in atherosclerotic lesions can modify 
LDL in vitro through oxidative processes [5-81. Since 
exact mechanisms by which cells oxidize LDL remain 
uncertain, it would be important to identify conditions 
which either increase or decrease LDL oxidation. The 
use of compounds that generate NO provide one promis- 
ing approach in this kind of studies. 
Recently, Jessup et al. [18] reported indirect evidence 
that NO inhibits LDL oxidation by macrophages. They 
kD 1 2 3 4 
- 
205 - 
Fig. 3. Effect of the NO donor GEA 3162 on the breakdown of apolipo- 
protein B during endothelial cell-mediated oxidation of LDL. Unla- 
beled LDL (6O&ml) was incubated with rabbit aortic endothelial cells 
in serum-free Optimen-1 for 24 h in the presence or absence of the NO 
donor (3.3 PM). LDL was then reisolated using ultracentrifugation and 
subjected to 415% SDS-PAGE and immunoblotting. Immunoblot was 
done using a polyclonal anti-LDL antiserum YE (dilution 1:200). Lane 
1: Molecular weight markers; lane 2: Control LDL; lane 3: LDL oxi- 
dized by endothelial cells; lane 4: LDL incubated with endothelial cells 
in the presence of the NO donor. An arrow indicates the position of 
intact apolipoprotein B-100. Each lane contains 20 pg protein. 
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Fig. 4. Degradation of “‘1-LDL (5 ,@ml) in mouse peritoneal macro- 
phages after incubation with endothelial cells in the presence or absence 
of the NO donor GEA 3162 as indicated in the legend for Fig. 2A. 
Endothelial cell incubation medium was filtered, supplemented with 5% 
lipoprotein deficient serum and incubated with macrophages for 24 h. 
Macrophages were then analyzed for (A) LDL degradation products 
and (B) cell-associated radioactivity. Results are expressed as percent- 
ages of control values f SE. (three separate xperiments). C, control 
LDL; EC, endothelial cell-treated LDL; EC + GEA, the effect of GEA 
3162 on the endothelial cell-mediated oxidation of LDL. 
found that y-interferon-stimulated macrophages, in 
which NO production is increased, did not oxidize LDL 
as well as unstimulated macrophages. Although y-inter- 
feron induces several other changes in macrophages be- 
sides an increased NO production, their results are com- 
patable with our findings and suggest a protective role 
of NO against cell-mediated LDL oxidation. Similar 
findings were also reported by Yates et al. [31]. 
Jessup et al. [18] also tested the effects of another NO 
donor, SIN-l, on the oxidation of LDL. SIN-l under- 
goes an oxygen-dependent release of NO with the con- 
comitant production of 0; [32]. They found that SIN-l 
increased the content of LDL hydroperoxides but did 
not convert LDL into a form recognized by macro- 
phages. However, the direct effects of SIN-l on the mac- 
rophage-mediated oxidation of LDL were not tested. In 
a cell-free system, Darley-Usmar et al. [l l] and Graham 
et al. [ 171 have demonstrated that SIN-l is able to oxidize 
LDL, while NO generated from sodium nitroprusside or 
S-nitroso-n-acetylpenicillamine was virtually ineffective. 
In the present study, GEA 3162 reduced lipid hydro- 
peroxide formation (measured as hydroxy acids), which 
could indicate that the compound does not produce 0; 
simultaneously with the NO release. This agrees with our 
findings that SIN-l, but not GEA 3162, increases LDL 
electrophoretic mobility. Also, in a cell-free system SIN- 
1 (100 PM) increased LDL degradation by mouse mac- 
rophages 2-fold (Malo-Ranta et al., unpublished obser- 
vations). In contrast to GEA 3162, SIN-l also caused a 
strong spontaneous chemiluminescence in an oxygenated 
aqueous environment at biologically active concentra- 
tions [19]. The rate and kinetics of nitrite production 
from GEA 3162 and SIN-l were quite different: GEA 
3162 generated NO quickly and the nitrite production 
started to decline already in a few minutes, while the 
production of nitrite from SIN-l was slower and more 
persistent. The rates are in a good agreement with the 
reported production of NO from GEA 3 162 and SIN- 1, 
as measured by the oxyhaemoglobin method [20]. Al- 
though the exact mechanism of NO release by GEA 3 162 
is unknown, these data indicate differences between SIN- 
1 and GEA 3162 with respect o the generation of NO. 
The inhibitory effect of GEA 3162 on the EC-medi- 
ated oxidation of LDL could be related to the stimula- 
tion of soluble guanylate cyclase by NO [13] or to the 
inhibitory effect of NO on 15lipoxygenase activity [33]. 
It is also possible that NO or a product derived from 
GEA 3162 can scavenge radicals [34] or chelate iron or 
other components needed for LDL oxidation [l 1 ,18,33]. 
Further studies are needed to define actual mechanisms 
responsible for the inhibitory effect of the NO donor 
GEA 3162 on the EC-mediated oxidation of LDL. 
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